Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 1/20 | 0.54 |
| ▸ | AGTR1 | P30556 | 3/20 | 0.49 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.49 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.49 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21125120 | 0.86 | TSHR (0.47) | DHODHCYP3A4ADORA3CYP2C9TBXAS1 | |
| SCHEMBL25963850 | 0.85 | AGTR1 (0.48) | DHODHAGTR1ABCB11EGFRERBB2 | |
| SCHEMBL30206716 | 0.84 | AGTR1 (0.48) | DHODHAGTR1ABCB11EGFRERBB2 | |
| SCHEMBL21125116 | 0.83 | AGTR1 (0.47) | DHODHAGTR1ABCB11EGFRERBB2 | |
| SCHEMBL5319554 | 0.80 | AGTR1 (0.52) | DHODHAGTR1ABCB11EGFRERBB2 | |
| SCHEMBL22533560 | 0.78 | AGTR1 (0.62) | AGTR1ABCB11EGFRERBB2CYP3A4 | |
| SCHEMBL8265591 | 0.77 | AGTR1 (0.64) | AGTR1ABCB11EGFRERBB2CYP3A4 | |
| SCHEMBL4244121 | 0.75 | AGTR1 (0.61) | AGTR1ABCB11EGFRERBB2CYP3A4 | |
| SCHEMBL3975959 | 0.75 | AGTR1 (0.75) | AGTR1ABCB11EGFRERBB2CYP3A4 | |
| SCHEMBL3945157 | 0.73 | AGTR1 (0.46) | DHODHAGTR1ABCB11EGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2480224-B1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF MCP-1 MEDIATED INFLAMMATORY DISEASES | ACRAF (IT) | 2017-05-24 | — | — | EP | disclosed |
| US-9492542-B2 | Pharmaceutical composition for the treatment of MCP-1 mediated inflammatory diseases | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2016-11-15 | — | — | US | disclosed |
| US-8569528-B2 | Process for the preparation of tetrazole derivatives from organo boron and organo aluminium azides | NOVARTIS AG (CH) | 2013-10-29 | — | — | US | disclosed |
| US-8569528-B2 | Process for the preparation of tetrazole derivatives from organo boron and organo aluminium azides | NOVARTIS AG (CH) | 2013-10-29 | — | — | US | disclosed |
| US-20120330026-A1 | PROCESS FOR THE PREPARATION OF TETRAZOLE DERIVATIVES FROM ORGANO BORON AND ORGANO ALUMINIUM AZIDES | NOVARTIS AG (CH) | 2012-12-27 | — | — | US | disclosed |
| US-20120330026-A1 | PROCESS FOR THE PREPARATION OF TETRAZOLE DERIVATIVES FROM ORGANO BORON AND ORGANO ALUMINIUM AZIDES | NOVARTIS AG (CH) | 2012-12-27 | — | — | US | disclosed |
| US-20120220636-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF MCP-1 MEDIATED INFLAMMATORY DISEASES | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F.S.P.A. (IT) | 2012-08-30 | — | — | US | disclosed |
| US-20110184187-A1 | PROCESS FOR THE PREPARATION OF TETRAZOLE DERIVATIVES FROM ORGANO BORON AND ORGANO ALUMINIUM AZIDES | SEDELMEIER GOTTFRIED | 2011-07-28 | — | — | US | disclosed |
| US-20110184187-A1 | PROCESS FOR THE PREPARATION OF TETRAZOLE DERIVATIVES FROM ORGANO BORON AND ORGANO ALUMINIUM AZIDES | SEDELMEIER GOTTFRIED | 2011-07-28 | — | — | US | disclosed |
| US-7943647-B2 | Process for the preparation of tetrazole derivatives from organo aluminium azides | NOVARTIS AG (CH) | 2011-05-17 | — | — | US | disclosed |
| US-7345072-B2 | Phenyltetrazole compounds | DIPHARMA S.P.A. (IT) | 2008-03-18 | — | — | US | disclosed |
| US-7345072-B2 | Phenyltetrazole compounds | DIPHARMA S.P.A. (IT) | 2008-03-18 | — | — | US | disclosed |
| US-7307096-B2 | Combined agents for treatment of glaucoma | SANKYO COMPANY, LIMITED (JP) | 2007-12-11 | — | — | US | disclosed |
| EP-1555260-B1 | Phenyltetrazole compounds | DIPHARMA FRANCIS SRL (IT) | 2007-09-19 | — | — | EP | disclosed |
| US-20070093540-A1 | PROCESS FOR THE PREPARATION OF ANGIOTENSIN II ANTAGONISTIC COMPOUNDS | DIPHARMA S.P.A. (IT) | 2007-04-26 | — | — | US | disclosed |
| US-20070093540-A1 | PROCESS FOR THE PREPARATION OF ANGIOTENSIN II ANTAGONISTIC COMPOUNDS | DIPHARMA S.P.A. (IT) | 2007-04-26 | — | — | US | disclosed |
| US-20070043098-A1 | Process for the preparation of tetrazole derivatives from organo boron and organo aluminium azides | NOVARTIS PHARMACEUTICALS CORPORATION | 2007-02-22 | — | — | US | disclosed |
| WO-2005020971-A1 | USE OF AN ANGIOTENSIN II ANTAGONIST FOR THE PREVENTION OF MYOCARDIAL INFARCTION | ASTRAZENECA AB (SE) | 2005-03-10 | — | — | WO | disclosed |
| WO-2005014602-A1 | PROCESS FOR THE PREPARATION OF TETRAZOLE DERIVATIVES FROM ORGANO BORON AND ORGANO ALUMINIUM AZIDES | NOVARTIS AG (CH) | 2005-02-17 | — | — | WO | disclosed |
| WO-2004087136-A1 | USE OF ATII ANTAGONIST FOR THE TREATMENT OR PREVENTION OF METABOLIC SYNDROME | ASTRAZENECA AB (SE) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043098-A1 | Process for the preparation of tetrazole derivatives from organo boron and organo aluminium azides | ABL1, TBCA, TBC1D5 | DHODH 2211/4885AGTR1 2005/4885ABCB11 1648/4885 |
| US-20120330026-A1 | PROCESS FOR THE PREPARATION OF TETRAZOLE DERIVATIVES FROM ORGANO BORON AND ORGANO ALUMINIUM AZIDES | ABL1, TBCA, TBC1D5 | DHODH 2211/4885AGTR1 2005/4885ABCB11 1648/4885 |
| US-20110184187-A1 | PROCESS FOR THE PREPARATION OF TETRAZOLE DERIVATIVES FROM ORGANO BORON AND ORGANO ALUMINIUM AZIDES | ABL1, TBCA, TBC1D5 | DHODH 2211/4885AGTR1 2005/4885ABCB11 1648/4885 |
| US-20120220636-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF MCP-1 MEDIATED INFLAMMATORY DISEASES | ACE, ACE2, CCL11 | DHODH 3664/4885AGTR1 6/4885ABCB11 293/4885 |
| US-20070093540-A1 | PROCESS FOR THE PREPARATION OF ANGIOTENSIN II ANTAGONISTIC COMPOUNDS | AGTR2, AGTR1, ACE2 | DHODH 656/4885AGTR1 2/4885ABCB11 4043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.